Provided by Tiger Trade Technology Pte. Ltd.

Incyte

123.28
-2.7300-2.17%
Post-market: 124.481.20+0.97%18:42 EDT
Volume:1.46M
Turnover:181.20M
Market Cap:24.99B
PE:15.70
High:126.31
Open:125.09
Low:122.58
Close:126.01
52wk High:132.60
52wk Low:81.09
Shares:202.70M
Float Shares:169.82M
Volume Ratio:1.07
T/O Rate:0.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):7.85
EPS(LYR):6.41
ROE:30.67%
ROA:16.83%
PB:3.94
PE(LYR):19.23

Loading ...

Incyte price target raised to $134 from $117 at Barclays

TIPRANKS
·
Jul 14

Incyte Corp. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Jul 14

Hemab Therapeutics' HMB-002 Well Suited for Type 1 Von Willebrand Disease, Wedbush Says

MT Newswires Live
·
Jul 13

Jefferies Adjusts Price Target on Incyte to $105 From $100, Maintains Hold Rating

MT Newswires Live
·
Jul 13

Incyte announces safety, efficacy data from VGA039 study

TIPRANKS
·
Jul 13

Incyte's Latarcibart Cuts Bleeding Rates in Phase 1/2 Trial in Patients With von Willebrand Disease

MT Newswires Live
·
Jul 13

Incyte - Phase 3 Vivid-6 Trial of Latarcibart for Vwd Currently Enrolling

THOMSON REUTERS
·
Jul 13

Incyte - Latarcibart Treatment Led to 81% Median Reduction in Annualized Bleeding Rate in Vwd

THOMSON REUTERS
·
Jul 13

Incyte - Presents Phase 1/2 Data for Latarcibart Showing Substantial Bleed Reductions in Vwd Patients

THOMSON REUTERS
·
Jul 13

Incyte Says Phase 1/2 Data Show 81% Median Bleed-rate Cut with VWD Drug Latarcibart

Reuters
·
Jul 13

Incyte (INCY) Could Be 8% Overvalued After Its 22% Three Month Run

Simply Wall St.
·
Jul 13

Incyte Corp. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Jul 11

Does Opzelura’s EU Setback and Index Exit Reframe the Bull Case For Incyte (INCY)?

Simply Wall St.
·
Jul 10

Incyte Corp. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 10

Press Release: Incyte to Report Second Quarter Financial Results

Dow Jones
·
Jul 08

Incyte Schedules Second-quarter Results Conference Call and Webcast

Reuters
·
Jul 08

Incyte is Maintained at Sector Perform by RBC Capital

Dow Jones
·
Jul 07

RBC Capital Adjusts Incyte Price Target to $99 From $95, Maintains Sector Perform Rating

MT Newswires Live
·
Jul 07

Adagene Posts Investor Presentation Highlighting Adg126 Masked Anti-ctla-4 Program in MSS Colorectal Cancer

Reuters
·
Jul 07

Incyte Corp. Stock Underperforms Monday When Compared to Competitors

Dow Jones
·
Jul 07